Document is current
Any future updates will be listed below
-
Authors
Li, Zhihao https://orcid.org/0000-0002-5654-7043
Chen, Itsuko Chih-Yi
Centonze, Leonardo https://orcid.org/0000-0001-9371-7411
Magyar, Christian T. J. https://orcid.org/0000-0002-4570-949X
Choi, Woo Jin
Ivanics, Tommy
O’Kane, Grainne M. https://orcid.org/0000-0002-8690-403X
Vogel, Arndt
Erdman, Lauren
De Carlis, Luciano
Lerut, Jan
Lai, Quirino
Agopian, Vatche G.
Mehta, Neil
Chen, Chao-Long
Sapisochin, Gonzalo
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 25 June 2025
First Online: 9 July 2025
Competing interests
: G.S. discloses consultancy for Astra-Zeneca, Roche, Evidera, Novartis, HepaRegenix, and Integra. G.S. has received financial compensation for talks for Roche, Astra-Zeneca, Chiesi, and Integra. G.S. has received a grant from Roche. N.M. discloses consultancy for Genentech, FujiFilm Wako, Merck, Eisai, Exact Sciences. N.M. has received a grant from Genentech, FujiFilm Wako, TARGET Pharmasolutions, Exact Sciences. A.V. had been directly paid honoraria and has been paid consulting or advisory roles for AstraZeneca, BeiGene, Boehringer Mannheim, BMS, BTG, EISAI, GSK, Incyte, Ipsen, MSD, Hoffmann-La Roche, Servier, Sirtex, and Taiho. G.O’.K. has received grants from Roche and AstraZeneca; consulting fees from AstraZeneca, Servier, and Incyte; payment for lectures from Roche, and support for attending meetings from MSD and Roche. None of the other authors have any competing interests to declare.
